The Pharmaceutical Market

Summary

Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

The tax-funded National Health system (SNS) underwent a process of decentralisation through which managerial and economic responsibility was devolved to the 17 regions by December 2001. Public hospitals are owned by the state but funded by the regions. However, there have been some experiences towards private management of public hospitals, with public funding. The private health insurance sector has grown in recent years but is still small; there are around eight million people fully insured.

Pharmaceuticals are classified as hospital and retail pharmacy drugs. Market authorisation and pricing & reimbursement remain at a national level, whilst the regions have implemented their own pharmaceutical policies, addressing prescribers and medical representatives particularly. Reimbursement of medicines is selective. Hospital drugs are provided free of charge. For retail pharmacy drugs, co-payment levels are very low, ranging from 0% to 40% for retail drugs. There has been a new reference price system in place since March 2007.

The Spanish pharmaceutical market is the fifth largest in the EU-27. The pharmacy sector represents 76.2% of the market at manufacturers' prices, the remaining 23.8% being hospital sales. Pharmaceutical production continues to increase but recent measures introduced by the government have resulted in slower R&D growth. In July 2006, Spain enforced a new pharmaceutical law. Its development has been polemical, as many industry representatives feel that the government has pushed a law without consensus.

Almirall and Esteve are the leading domestic pharmaceutical producers, with sales of over US$1.0 billion. In October 2007, Almirall entered an agreement to acquire an eight-product portfolio from the UK's Shire Pharmaceuticals. This followed Almirall's acquisition of the German producer Hermal in September 2007. Esteve continues to enhance its market presence in China. Almirall and Esteve's R&D investments have risen sharply in recent years.

Contents

• Background Data
• Geography
• Political Overview
• Economic Overview
• Population
• Demographic Indicators
• Mortality
• Morbidity
  • Aids
  • Charts
  • Map of Spain
  • Population by Region & Age, 2007 (%)
  • Leading Causes of Death, 2006 (%)
  • Aids Cases, 1981-2006
  • Aids Cases, 1991-2006 (Rate per Million Population)
• Healthcare System
• Organisation & Administration
  • Health Cohesion & Quality Law
  • Private Health Insurance
• Health Expenditure
  • Public Health Expenditure
• Hospital Services
  • Hospital Activity
• Healthcare System
• Ambulatory Care
• Medical Personnel
  • Public Personnel
  • Charts
  • First Consultations by Specialty as Percentage of Total, 2005
  • Diagnostic Procedures by Sector, 2005 (%)
  • Surgical Procedures by Sector & Specialty, 2005 (%)
  • Births by Provision, 2005
  • Registered Doctors, 1999-2006
  • Doctors in Public Health Centres with Specialties & Hospitals by Specialty, 2005 (%)
• Accessing The Pharmaceutical
• Market
• Accessing The Pharmaceutical Market
• Introduction
• Regulatory Environment
  • National Procedure
  • Human Medicines
  • Patent Protection & Intellectual Property Rights
  • Pricing & Reimbursement
  • Promotion
• Distribution Channels
  • Distributors
• Aragofar
• Cecofar
• Cofares
• Federaci Farmacutica
• Hefame
• Safa
  • Pharmacies
• Trade Fairs
• Biospain
• Farmamaq
• Fisalud
• Infarma
• Domestic Production
  • Trade Associations
• Aeseg
• Anefp
• Accessing The Pharmaceutical Market
• Asebio
• Farmaindustria
  • Domestic Producers
• Almirall
• Cantabria Farmacutica
• Esteve
• Faes
• Ferrer Internacional
• Grifols
• Lcer
• Salvat
• Uriach
• Zeltia
  • Research & Development
• Directory
  • Government Organisations
  • Trade Associations
  • Human Medicines Authorisations, 1990-2006
  • Pharmacies by Region, 2006
  • Ferrer's Sales by Therapeutic Area, (%)
  • Change in Pharmaceutical R&d Expenditure, 2001-2006 (%)